75N91024D00003

PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ CONTRACT IN SUPPORT OF THE PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM

Unknown·Jan 2024 — Jul 2024

Total Obligated

AWARDED541714

No Signals

1 modification·Bidders unknown

Financial Summary

Total Obligated

Current Value

Potential Value

Timeline

Jan 2024

Award Date

Jul 2024

Completion Date

180 days

Duration

FY2024

Fiscal Year

Competition

—

Bidders

—

Contracting Details

Awarding AgencyUnknown

Awarding OfficeUnknown

NAICS541714

Created Byfpds_records

Procurement OfficeAvailable in Enterprise plan

Modifications

Original: $0Change orders: $0+0%

Mod	Date	Amount	Cumulative	Action
0	Jan 2024	—	—	initial_award

Awarded To

THE INSTITUTE FOR CANCER RESEARCH

UEI: FF1XVJMDYVR1

View company profile →

Similar Contracts

-NONE-

Unknown — CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA

$150.8M

-NONE-

Unknown — THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESIS...

$92.5M

-NONE-

Unknown — DPMWP 217/CDRH-2022-112765 - DEVELOP STANDARDS FOR DATA QUAL...

$47.1M

75A50119D00018

Unknown — MAPP 2019 CONTRACT

$37.5M

75A50122D00020

Unknown — BIO-AMT-2303: GLP NATURAL HISTORY STUDIES IN NHP MODELS OF F...

$6.9M

Statistical observations derived from public procurement data. Patterns identified do not constitute findings, accusations, or allegations of wrongdoing. All analysis is based on publicly available records and requires independent verification before any action is taken. This is not legal advice. Terms of Service